Denmark. Chr. Hansen Holding A/S
| Date of agreement: | 22 May 2015 |
|---|---|
| Country: | Denmark |
| Customer: | Chr. Hansen Holding A/S |
| Amount in DKK: | DKK 373 million |
| Amount in EUR: | EUR 50 million |
| Maturity: | 7 years |
| NACE sector / loan type: | Research and development |
Project
The loan has been provided to finance Chr. Hansen’s research and development activities in 2015–2016, focusing on identifying and developing natural ingredient solutions for the global food and health industries.
The aim of the R&D programme is to deliver innovative new products and to optimise processes through advanced bioprocess engineering and microbial physiology.
Chr. Hansen A/S, founded in 1874, develops and supplies speciality ingredients to the global food and beverage, pharmaceutical and agriculture industries. Its fundamental research activities are carried out in Denmark, while its main productions sites are based in Germany and the US. The company has 2,500 employees in over 30 countries.
Fulfilment of NIB's mandate
Chr. Hansen is a pioneer in probiotics and its portfolio features some of the best-documented bacterial strains. The R&D programme is geared towards customer needs and employs leading enzyme technology to deliver unique bio-solutions for a wide range of industries. A number of their products currently in development, such as probiotics, are likely to have a positive impact on human and animal health.
Chr. Hansen is actively entering into partnerships with other biotech companies, universities and researchers across disciplines to execute projects in their specialised field.
Sustainability summary
No significant environmental issues are connected to the R&D programme.
